Medivation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Medivation sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed early-phase tilt top decile by trial count

Medivation: 9 sponsored US clinical trials, none currently recruiting.

Medivation sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Huntington Disease, with 1 trials.

Top-decile sponsor footprint

Medivation ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 2

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

NCT01435369
COMPLETED Phase 3

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

NCT00920946
COMPLETED Phase 2

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305
COMPLETED Phase 3

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
COMPLETED Phase 1

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

NCT00829816
COMPLETED Phase 3

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

NCT00675623
TERMINATED Phase 2

Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

NCT00704782
COMPLETED Phase 2

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

NCT00497159
COMPLETED Phase 1

Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

NCT00387270

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 3

Therapeutic Areas

Huntington Disease 1

How the Medivation early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Huntington Disease (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Medivation: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Medivation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Medivation4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Medivation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Medivation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Medivation page

9 registered trials is a research-attention snapshot, not an endorsement of Medivation or any single study.

  • None of Medivation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Huntington Disease is the condition Medivation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Huntington Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Medivation pipeline card: 9 registered trials from official public datasets.Report a data error.